{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:03:54Z","timestamp":1793833434160,"version":"4.6.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diagmicrobio.2025.116978","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:43:17Z","timestamp":1750851797000},"page":"116978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel heterocycles as antitubercular drugs: A review"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-5732","authenticated-orcid":false,"given":"Emranul","family":"Kabir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-4160","authenticated-orcid":false,"given":"Mahbub","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Ismail","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0001","doi-asserted-by":"crossref","first-page":"S679","DOI":"10.5530\/ijper.51.4s.99","article-title":"Synthesis and biological activity of novel 2,5-dichloro-3-acetylthiophene chalcone derivatives","volume":"51","author":"Lokesh","year":"2017","journal-title":"Indian J Pharm Educ Res"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.biopha.2011.04.005","article-title":"A review on various heterocyclic moieties and their antitubercular activity","volume":"65","author":"Sharma","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0003","first-page":"2947","article-title":"Importance of heterocyclic chemistry: a review","volume":"3","author":"Arora","year":"2012","journal-title":"IJPSR"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13835","article-title":"Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity","volume":"33","author":"Zhou","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.procbio.2022.06.009","article-title":"Pharmacological significance of nitrogen-containing five and six-membered heterocyclic scaffolds as potent cholinesterase inhibitors for drug discovery","volume":"120","author":"Obaid","year":"2022","journal-title":"Process Biochem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0006","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2416604","article-title":"Construction of circRNA\u2013miRNA\u2013mRNA ceRNA regulatory network and screening of diagnostic targets for tuberculosis","volume":"56","author":"Pu","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0007","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.rmed.2006.08.006","article-title":"The history of tuberculosis","volume":"100","author":"Daniel","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0008","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cpt.2261","article-title":"The treatment of tuberculosis","volume":"110","author":"Peloquin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00098-2018","article-title":"The World Health Organization standards for tuberculosis care and management","volume":"51","author":"Gilpin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMra1200894","article-title":"Tuberculosis","volume":"368","author":"Zumla","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0011","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2165\/11538170-000000000-00000","article-title":"Drugs in development for tuberculosis","volume":"70","author":"Ginsberg","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/pathogens12030362","article-title":"Management of tuberculosis infection: current situation, recent developments and operational challenges","volume":"12","author":"Agbota","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265068","article-title":"Antitubercular activity assessment of fluorinated chalcones, 2-aminopyridine-3-carbonitrile and 2-amino-4H-pyran-3-carbonitrile derivatives: In vitro, molecular docking and in-silico drug likeliness studies","volume":"17","author":"Lagu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0014","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11030-018-9839-y","article-title":"Structure\u2013activity relationship investigation of coumarin\u2013chalcone hybrids with diverse side-chains as acetylcholinesterase and butyrylcholinesterase inhibitors","volume":"22","author":"Kang","year":"2018","journal-title":"Mol Divers"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0015","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1002\/agt2.715","article-title":"Advancing aggregation-induced emission-derived biomaterials in viral, tuberculosis, and fungal infectious diseases","volume":"6","author":"Wang","year":"2024","journal-title":"Aggregate"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0016","doi-asserted-by":"crossref","first-page":"m216","DOI":"10.1136\/bmj.m216","article-title":"Current and future treatments for tuberculosis","author":"Lee","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0017","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/antibiotics11121680","article-title":"Synthetic imidazopyridine-based derivatives as potential inhibitors against multi-drug resistant bacterial infections: a review","volume":"11","author":"R","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0040-1722535","article-title":"Adverse drug reactions with first-line and second-line drugs in treatment of tuberculosis","volume":"57","author":"Prasad","year":"2021","journal-title":"Ann Natl Acad Med Sci"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0019","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/IDR.S68351","article-title":"New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid","volume":"8","author":"Brigden","year":"2015","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0020","article-title":"NIR-II AIE luminogen-based erythrocyte-like nanoparticles with granuloma-targeting and self-oxygenation characteristics for combined phototherapy of tuberculosis","volume":"36","author":"Wang","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0021","first-page":"1104","article-title":"Morbidity and Mortality Weekly Report","volume":"63","author":"Dokubo","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0022","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(00)02124-3","article-title":"Directly observed therapy and treatment adherence","volume":"355","author":"Volmink","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0023","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection\u2014the promise and the challenges","volume":"56","author":"Fox","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/crj.12119","article-title":"Challenges of antituberculosis treatment in patients with difficult clinical conditions","volume":"9","author":"Vasakova","year":"2015","journal-title":"Clin Respir J"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijid.2016.12.024","article-title":"New tuberculosis drug leads from naturally occurring compounds","volume":"56","author":"Quan","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0026","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cegh.2013.02.003","article-title":"Multi drug and extensively drug-resistant TB (M\/XDR-TB) management: current issues","volume":"1","author":"Prasad","year":"2013","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0027","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijtb.2017.03.006","article-title":"Extensively drug-resistant tuberculosis (XDR-TB): a daunting challenge to the current end TB Strategy and policy recommendations","volume":"64","author":"Rahman","year":"2017","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.52711\/2231-5691.2023.00005","article-title":"Side effects of TB therapy and recent therapeutic approaches for tuberculosis management","author":"Bandgar","year":"2023","journal-title":"Asian J Pharm Res"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0029","doi-asserted-by":"crossref","first-page":"20262","DOI":"10.1021\/acsomega.2c07267","article-title":"Synthesis, characterization, antitubercular activity, and molecular docking studies of pyrazolylpyrazoline-clubbed triazole and tetrazole hybrids","volume":"8","author":"Zala","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0030","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1039\/D2MD00155A","article-title":"Synthesis, biological evaluation and computational studies of pyrazole derivatives as Mycobacterium tuberculosis CYP121A1 inhibitors","volume":"13","author":"Alshabani","year":"2022","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2006.08.004","article-title":"Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives","volume":"42","author":"Ali","year":"2007","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0032","first-page":"677","article-title":"Design, synthesis, docking and biological study of pyrazole-3,5-diamine derivatives with potent antitubercular activity","volume":"6","author":"Pawar","year":"2022","journal-title":"Chem Methodol"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0033","doi-asserted-by":"crossref","first-page":"073","DOI":"10.7324\/JAPS.2023.119430","article-title":"Antimicrobial and antitubercular activity of novel pyrazole-4-carboxamide derivatives: synthesis and characterization","author":"Deepthi","year":"2023","journal-title":"J Appl Pharm Sci"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0034","article-title":"Synthesis, molecular docking, molecular dynamic simulation studies, and antitubercular activity evaluation of substituted benzimidazole derivatives","volume":"2024","author":"Thapa","year":"2024","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0035","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1080\/07391102.2022.2036241","article-title":"Design, synthesis, and computational studies of benzimidazole derivatives as new antitubercular agents","volume":"41","author":"Yalcin-Ozkat","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.116978_bib0036","first-page":"1184","article-title":"Structural characterization and antimycobacterial evaluation of a benzimidazole analogue of the antituberculosis clinical drug candidate TBA-7371","volume":"78","author":"Richter","year":"2022","journal-title":"Struct Rep"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0037","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1021\/acsmedchemlett.9b00343","article-title":"Scaffold morphing to identify novel dpre1 inhibitors with antimycobacterial activity","volume":"10","author":"R","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106904","article-title":"Synthesis, characterization, in vitro antimycobacterial and cytotoxicity evaluation, DFT calculations, molecular docking and ADME studies of new isomeric benzimidazole-1,2,3-triazole-quinoline hybrid mixtures","volume":"141","author":"Nyoni","year":"2023","journal-title":"Bioorg Chem"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116978_bib0039","article-title":"Design, synthesis and antimycobacterial activity of 2-(Benzimidazol-2-yl)-propanenitrile analogs","volume":"42","author":"Tan","year":"2022","journal-title":"Hacet Univ J Fac Pharm"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115611","article-title":"2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1","volume":"258","author":"Finger","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116297","article-title":"Discovery of 2,9-diaryl-6-carbamoylpurines as a novel class of antitubercular agents","volume":"268","author":"Correia","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116978_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000053","article-title":"Synthesis of 6-[4-(4-Propoxyphenyl)piperazin-1-yl]-9 H -purine derivatives as antimycobacterial and antifungal agents: In Vitro Evaluation and In Silico Study","volume":"17","author":"Nadaf","year":"2020","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0043","article-title":"Thiadiazole-thiazole derivatives as potent anti-tubercular agents: synthesis, biological evaluation, and in silico docking studies","author":"Shaikh","year":"2024","journal-title":"Eur J Med Chem Rep"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2025.116978_bib0044","article-title":"Four components one-pot synthesis of new Thiazoles and their biological screening for anti-tuberculosis activity","volume":"42","author":"V","year":"2023","journal-title":"J Chem Chem Eng Res Artic"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0045","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.5530\/ctbp.2024.2.27","article-title":"Synthesis, charectertisation and antitubercular evaluation of Pyarzoline clubbed thiazole hybrids","volume":"18","author":"Gopal","year":"2024","journal-title":"Curr Trends Biotechnol Pharm"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0046","doi-asserted-by":"crossref","unstructured":"N. Bhoge, B. Magare, P. Mohite, S. Dnyaneshwar Mahavidyalaya, Synthesis and biological evaluation of 3 (Benzo[d]Thiazol-2-yl)-2-(Substituted Aryl) thiazolidin-4-one derivatives, (2023). https:\/\/doi.org\/10.33263\/LIANBS131.019.","DOI":"10.33263\/LIANBS131.019"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0047","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.3390\/molecules27248807","article-title":"Development of novel Isatin-Tethered quinolines as anti-tubercular agents against multi and extensively drug-resistant mycobacterium tuberculosis","volume":"27","author":"Abdelrahman","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114531","article-title":"Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis","volume":"239","author":"Alcaraz","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0049","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1039\/D2MD00260D","article-title":"Novel quinoline-piperazine hybrids: the design, synthesis and evaluation of antibacterial and antituberculosis properties","volume":"14","author":"Gnanavelu","year":"2023","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0050","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/slct.201602022","article-title":"New quinoline linked chalcone and pyrazoline conjugates: molecular properties prediction, antimicrobial and antitubercular activities","volume":"2","author":"Rao","year":"2017","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0051","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/slct.201702279","article-title":"Design, docking, and synthesis of quinoline-2 H -1,2,4-triazol-3(4 H)-ones as potent anticancer and antitubercular agents","volume":"3","author":"Somagond","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0052","unstructured":"A.P. Macabeo, M. Tristan, J. Quimque, K.S. Pueblos, Synthesis, antitubercular activity and molecular docking studies of benzyl-modified 8-Hydroxyquinolines, Philipp J Health Res Dev 23(3) 1-9."},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0053","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/hc-2020-0109","article-title":"Design, synthesis and study of antibacterial and antitubercular activity of quinoline hydrazone hybrids","volume":"26","author":"T G","year":"2020","journal-title":"Heterocycl Comm"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0054","first-page":"986","article-title":"Design and synthesis of new quinoline hybrid derivatives and their antimicrobial, antimalarial and antitubercular activities","volume":"60","author":"Lagdhir","year":"2021","journal-title":"Indian J Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103955","article-title":"Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents","volume":"100","author":"Srinivasarao","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0056","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.bmc.2010.02.024","article-title":"New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents","volume":"18","author":"Ancizu","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0057","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2009.10.026","article-title":"In vitro antitubercular and antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones","volume":"20","author":"Ramalingam","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0058","first-page":"353","article-title":"Synthesis of novel 4,5-dihydropyrrolo[1,2- a]quinoxalines, pyrrolo[1,2- a]quinoxalin]-2-ones and their antituberculosis and anticancer activity","author":"Makane","year":"2020","journal-title":"Arch Pharm (Weinh)"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127784","article-title":"Synthesis of novel quinoxaline-alkynyl derivatives and their anti-Mycobacterium tuberculosis activity","volume":"35","author":"Raphoko","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315295","article-title":"Synthesis, biological evaluation and computational studies of new hydrazide derivatives containing 1,3,4-oxadiazole as antitubercular agents","volume":"23","author":"Zampieri","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jksus.2023.102737","article-title":"Synthesis and anti-tubercular evaluation of some novel (E)-5-(4-(benzylidene amino) phenyl)-1,3,4-oxadiazole-2-thiol derivatives","volume":"35","author":"Das","year":"2023","journal-title":"J King Saud Univ Sci"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0062","first-page":"355","article-title":"One pot synthesis of 1,3,4-oxadiazoles by Lewis acid catalyst and their study of 2D-QSAR, antimicrobial and anti-tubercular activities","volume":"62","author":"Patel","year":"2023","journal-title":"Indian J Chem (IJC)"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116978_bib0063","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14756366.2021.1900162","article-title":"In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1, 2, 4-oxadiazole analogues against Mycobacterium tuberculosis","volume":"36","author":"Deb","year":"2021","journal-title":"J enzyme inhib med chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0064","doi-asserted-by":"crossref","first-page":"337","DOI":"10.32628\/IJSRST229630","article-title":"Synthesis and in-silico study of novel 1,3,4-oxadiazole derivatives : a biologically active scaffolds which induce anti-tubercular activity by targeting pteridine reductase and dihydrofolate reductase","author":"Jadhav","year":"2022","journal-title":"Int J Sci Res Sci Technol"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/a-1252-2378","article-title":"Evaluation and docking study of pyrazine containing 1, 3, 4-oxadiazoles clubbed with substituted azetidin-2-one: a new class of potential antimicrobial and antitubercular","volume":"71","author":"Das","year":"2021","journal-title":"Drug Res"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0066","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/molecules23081945","article-title":"Ultrasound assisted synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) benzamide as challenging anti-tubercular scaffold","volume":"23","author":"Nimbalkar","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0067","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2229070","article-title":"Synthesis, antimycobacterial evaluation, and molecular docking study of 1,2,4-triazole derivatives","volume":"38","author":"Xia","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0068","doi-asserted-by":"crossref","unstructured":"A. Sayeed, M. W. Akram, Studies on the synthesis of some new 1, 2, 4-triazoles derivatives and evaluation for their anti-tubercular activity profiles, Res J Pharm Technol 11(1) 153-164.","DOI":"10.5958\/0974-360X.2018.00029.X"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0069","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.3390\/molecules25246033","article-title":"New application of 1,2,4-triazole derivatives as antitubercular agents. structure, in vitro screening and docking studies","volume":"25","author":"Karczmarzyk","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0070","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1016\/j.bmcl.2017.07.008","article-title":"Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents","volume":"27","author":"Ali","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0071","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2174\/1570180819666220829143739","article-title":"Some new 1,2,4-triazole derivatives bearing the pyrimidine moiety as potential antimycobacterial agents: synthesis and docking analysis","volume":"20","author":"Reddy","year":"2023","journal-title":"Lett Drug Discov"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0072","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1080\/07391102.2023.2217928","article-title":"Synthesis, antitubercular profile and molecular docking studies of quinazolinone-based pyridine derivatives against drug-resistant tuberculosis","volume":"42","author":"Raghu","year":"2024","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0073","first-page":"60","article-title":"Synthesis, characterization, and antitubercular evaluation of tetrahydrotetrazolo quinazoline derivatives","volume":"21","author":"Babu","year":"2023","journal-title":"Antiinfect Agents"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0074","article-title":"Nanomaterials in the prevention, diagnosis, and treatment of mycobacterium tuberculosis infections","volume":"7","author":"Xu","year":"2018","journal-title":"Adv Heal Mater"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0014-827X(00)00100-2","article-title":"Quinazoline derivatives with antitubercular activity","volume":"55","author":"Kune\u0161","year":"2000","journal-title":"Farmaco"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0076","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1039\/C8NJ04936J","article-title":"Facile synthesis of 1,4-benzodiazepine-2,5-diones and quinazolinones from amino acids as anti-tubercular agents","volume":"43","author":"Anil","year":"2019","journal-title":"New J Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103774","article-title":"Benzimidazoquinazolines as new potent anti-TB chemotypes: Design, synthesis, and biological evaluation","volume":"99","author":"Jadhavar","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0078","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijtb.2020.09.005","article-title":"Pretomanid: a novel therapeutic paradigm for treatment of drug resistant tuberculosis","volume":"68","author":"Parveen","year":"2021","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0079","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17512433.2016.1200462","article-title":"Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis","volume":"9","author":"Nguyen","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1183597","article-title":"Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0081","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1039\/D3MD00019B","article-title":"Recent developments of imidazo[1,2- a]pyridine analogues as antituberculosis agents","volume":"14","author":"Samanta","year":"2023","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0082","first-page":"1361","article-title":"Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis","volume":"33","author":"Qiujing","year":"2020","journal-title":"Pak J Pharm Sci"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116978_bib0083","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3987\/COM-08-S(N)30","article-title":"Synthetic studies on Mycobacterium tuberculosis specific fluorescent Park's nucleotide probe","volume":"76","author":"Li","year":"2008","journal-title":"Heterocycles"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0084","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-020-3004-3","article-title":"Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline","volume":"589","author":"Guo","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0086","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0087","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/0115680266286294240610102911","article-title":"Recent biochemical advances in antitubercular drugs: challenges and future","volume":"24","author":"Jain","year":"2024","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0088","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: Hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0089","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.diagmicrobio.2025.116978_sbref0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0091","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/children9081120","article-title":"Pediatric tuberculosis management: a global challenge or breakthrough?","volume":"9","author":"Maphalle","year":"2022","journal-title":"Children"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12992-024-01047-7","article-title":"Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of global drug facility product catalogs from 2001 to 2024","volume":"20","author":"Kohler","year":"2024","journal-title":"Glob Health"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2024.102573","article-title":"Quinoline hybrid derivatives as effective structural motifs in the treatment of tuberculosis: Emphasis on structure-activity relationships","volume":"149","author":"Hegde","year":"2024","journal-title":"Tuberculosis"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0094","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/antibiotics9050233","article-title":"Cytotoxicity and antimycobacterial properties of pyrrolo[1,2-a]quinoline derivatives: Molecular target identification and molecular docking studies","volume":"9","author":"Venugopala","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0095","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1039\/D4MD00377B","article-title":"Antitubercular evaluation of dihydropyridine-triazole conjugates: design, synthesis, in vitro screening, SAR and in silico ADME predictions","volume":"15","author":"Kushawaha","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0096","first-page":"1","article-title":"A brief overview on recent advances in the development of anti-tubercular compounds containing different heterocyclic ring systems","volume":"2","author":"Asif","year":"2016","journal-title":"Appl Microbiol: Open Access"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0097","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200618","article-title":"Thiazolidinone-heterocycle frameworks: a concise review of their pharmacological significance","volume":"18","author":"Seboletswe","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0098","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/ph16030377","article-title":"Anti-tuberculosis mur inhibitors: structural insights and the way ahead for development of novel agents","volume":"16","author":"Mehta","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115351","article-title":"Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents","volume":"255","author":"Wen","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00441-19","article-title":"1H-Benzo[d]Imidazole derivatives affect MmpL3 in mycobacterium tuberculosis","volume":"63","author":"Korycka-Macha\u0142a","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116978_bib0101","first-page":"15","article-title":"An overview on Benzothiazinone analogs as antitubercular drugs","volume":"3","author":"Asif","year":"2015","journal-title":"PharmaTutor"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0102","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diagmicrobio.2025.116978_bib0103","doi-asserted-by":"crossref","DOI":"10.1039\/D0RA10728J","article-title":"Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of Mycobacterium tuberculosis and paediatric brain tumour cells","volume":"11","author":"Alsayed","year":"2021","journal-title":"RSC Adv"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325003013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325003013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:17:41Z","timestamp":1762309061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325003013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0732889325003013"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116978","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel heterocycles as antitubercular drugs: A review","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116978"}}